Patents by Inventor Lubomir Sokol

Lubomir Sokol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of identifying myelodysplastic syndromes
    Patent number: 9487776
    Abstract: Myelodysplastic syndromes display both hematological and biological heterogeneity with variable leukemia potential. To determine whether microRNAs expression offers diagnostic discrimination or influences malignant potential in MDS, bone marrow miRNA expression was investigated from prognostically distinct MDS subsets using a microarray platform. After background subtraction and normalization, data were analyzed indicating thirteen miRNA signature with statistically significant differential expression, including down-regulation of members of a leukemia associated miRNA family. A unique signature consisting of 10 miRNAs was closely associated with International Prognostic Scoring System risk category permitting discrimination between lower and higher risk disease. Selective overexpression of miRNA-181 family members was detected in higher risk MDS, indicating pathogenetic overlap with acute myeloid leukemia.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: November 8, 2016
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Alan F. List, Lubomir Sokol
  • Method of Identifying Myelodysplastic Syndromes
    Publication number: 20120316081
    Abstract: Myelodysplastic syndromes display both hematological and biological heterogeneity with variable leukemia potential. To determine whether microRNAs expression offers diagnostic discrimination or influences malignant potential in MDS, bone marrow miRNA expression was investigated from prognostically distinct MDS subsets using a microarray platform. After background subtraction and normalization, data were analyzed indicating thirteen miRNA signature with statistically significant differential expression, including down-regulation of members of a leukemia associated miRNA family. A unique signature consisting of 10 miRNAs was closely associated with International Prognostic Scoring System risk category permitting discrimination between lower and higher risk disease. Selective overexpression of miRNA-181 family members was detected in higher risk MDS, indicating pathogenetic overlap with acute myeloid leukemia.
    Type: Application
    Filed: July 30, 2012
    Publication date: December 13, 2012
    Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Alan F. List, Lubomir Sokol